Genmark Diagnostics (GNMK) Stock Price, Quote, News and Overview
NASDAQ:GNMK - Nasdaq -
GNMK Quote, Performance and Key Statistics
24.04
0 (0%)
The current stock price of GNMK is 24.04 null. In the past month the price increased by 0.21%. In the past year, price increased by 116.19%.
About GNMK
Company Profile
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
Company Info
Genmark Diagnostics
5964 LA PLACE COURT
CARLSBAD CA 92008
CEO: Scott Mendel
Phone: 760-448-4300
Genmark Diagnostics / GNMK FAQ
What is the stock price of Genmark Diagnostics today?
The current stock price of GNMK is 24.04 null.
What is the ticker symbol for Genmark Diagnostics stock?
The exchange symbol of Genmark Diagnostics is GNMK and it is listed on the Nasdaq exchange.
On which exchange is GNMK stock listed?
GNMK stock is listed on the Nasdaq exchange.
What is Genmark Diagnostics worth?
Genmark Diagnostics (GNMK) has a market capitalization of 1.76B null. This makes GNMK a Small Cap stock.
What are the support and resistance levels for Genmark Diagnostics (GNMK) stock?
Genmark Diagnostics (GNMK) has a support level at 23.99 and a resistance level at 24.16. Check the full technical report for a detailed analysis of GNMK support and resistance levels.
Should I buy Genmark Diagnostics (GNMK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GNMK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GNMK, evaluating the profitability, health, valuation and growth aspects
- Genmark Diagnostics (GNMK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Genmark Diagnostics (GNMK) Sales and EPS estimates to see what analysts future expectations are.
- Genmark Diagnostics (GNMK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Genmark Diagnostics (GNMK) Insider and Institutional Ownership to learn about the owners and their transactions.
- Genmark Diagnostics (GNMK) Stock Chart to make your own analysis
- Genmark Diagnostics (GNMK) Latest news and press-releases to stay up to date.
Does Genmark Diagnostics (GNMK) stock pay dividends?
GNMK does not pay a dividend.
When does Genmark Diagnostics (GNMK) report earnings?
Genmark Diagnostics (GNMK) will report earnings on 2022-02-28, after the market close.
What is the Price/Earnings (PE) ratio of Genmark Diagnostics (GNMK)?
Genmark Diagnostics (GNMK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
GNMK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GNMK. When comparing the yearly performance of all stocks, GNMK is one of the better performing stocks in the market, outperforming 87.03% of all stocks.
GNMK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GNMK. While GNMK seems to be doing ok healthwise, there are quite some concerns on its profitability.
GNMK Financial Highlights
Over the last trailing twelve months GNMK reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 65.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10.87% | ||
| ROA | -8.34% | ||
| ROE | N/A | ||
| Debt/Equity | 0.76 |
GNMK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to GNMK. The Buy consensus is the average rating of analysts ratings from 6 analysts.